Enzymatic Assembly Line Overview
Earlier this year, research at the Kee-Hong Kim lab of Purdue University had preliminary evidence showing that a trans-stilbene compound, Piceatannol, had an ability to inhibit the development of human adipose cells. The mechanism is based around the idea that Piceatannol interacts with a preadipocyte's (immature fat cell) insulin receptors in such a way that surpresses it's growth into a mature adipose cell. Such a compound is a metabolite of a prime candidate for biochemical research, Resveratrol, which differs from Piceatannol only by an extra hydroxl group housed on one of its aromatic rings.
Piceatannol is currently very costly to synthesize. On the advent of such a discovery, we felt that if we were to engineer a pathway to optimize the production of Piceatannol from cheaper substrates through the utilization of our PUF and RNA scaffold projects, we could show the versatility of our PUF toolkit working with an RNA scaffold.
However, before research can begin in using our PUF toolkit to increase yields of in vivo E. coli compound production, our first steps involved acquiring and characterizing the necesary genes for our planned enzymatic assembly line. In total, our theoretical construct involves three main protein entities:
Enzymatic Assembly Line Overview
Earlier this year, research at the Kee-Hong Kim lab of Purdue University had preliminary evidence showing that a trans-stilbene compound, Piceatannol, had an ability to inhibit the development of human adipose cells. The mechanism is based around the idea that Piceatannol interacts with a preadipocyte's (immature fat cell) insulin receptors in such a way that surpresses it's growth into a mature adipose cell. Such a compound is a metabolite of a prime candidate for biochemical research, Resveratrol, which differs from Piceatannol only by an extra hydroxl group housed on one of its aromatic rings.
Piceatannol is currently very costly to synthesize. On the advent of such a discovery, we felt that if we were to engineer a pathway to optimize the production of Piceatannol from cheaper substrates through the utilization of our PUF and RNA scaffold projects, we could show the versatility of our PUF toolkit working with an RNA scaffold.
However, before research can begin in using our PUF toolkit to increase yields of in vivo E. coli compound production, our first steps involved acquiring and characterizing the necesary genes for our planned enzymatic assembly line. In total, our theoretical construct involves three main protein entities:
Design and Theory
The above is our theoretical construct involving the three aforementioned genes.
As labeled, the sequence of enzymatic activity begins at TAL, which converts the naturally present amino acid in E. Coli, Tyrosine, into p-Coumaric Acid.